AC Immune receives milestone payment for crenezumab moving into phase III clinical development in Alzheimer's disease
22.July 2015 08:00 CET
- Phase III clinical program to evaluate crenezumab in people with prodromal-to-mild Alzheimer's disease
- AC Immune receives milestone under 2006 collaboration with Genentech